undamentalytics Newsletter
Sign in

Enanta Pharmaceuticals Inc cash flow statement

In fiscal 2025, Enanta Pharmaceuticals Inc's operations generated −$19.3m of cash; it spent $12.9m on capital projects, leaving free cash flow of −$32.2m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Sept 20112012Sept 20122013Sept 20132014Sept 20142015Sept 20152016Sept 20162017Sept 20172018Sept 20182019Sept 20192020Sept 20202021Sept 20212022Sept 20222023Sept 20232024Sept 20242025Sept 2025LTMJun 2026
Cash from operations2423112077365329717−70−85−103−79−19−35
Depreciation and amortisation0000122334332255
Stock-based pay00136913161920212728271915
Capital spending001125335112918132
Free cash flow2422101974315026666−71−87−112−97−32−37
Free cash flow after stock pay23229166822371047−14−92−114−140−124−51−52
Shares issued——————167104—————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ABCL vs ENTACUVL vs ENTACYTK vs ENTA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Enanta Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Enanta Pharmaceuticals Inc.